VSIG4, CRIg, Z39IG
Recombinant Human VSIG4 Protein (rh VSIG4) Arg 20 - Pro 283 (Accession # AAH10525) was produced in human 293 cells (HEK293) at ACRObiosystems.
rh VSIG4, fused with 6×His tag at the C-terminus, has a calculated MW of 30 kDa. The predicted N-terminus is Arg 20. DTT-reduced Protein migrates as 45-48 kDa.
Less than 1.0 EU per μg of the rh VSIG4 by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
V-set and immunoglobulin domain-containing protein 4 (VSIG4) is also known as Protein Z39Ig, is a type I transmembrane glycoprotein. VSIG4 is a B7 family-related protein and an Ig superfamily member. VSIG4 contains two Ig-like (immunoglobulin-like) domains. VSIG4 is abundantly expressed in several fetal tissues. In adult tissues, the highest expression of VSIG4 is in lung and placenta. VSIG4 functions as a negative regulator of T cell activation, and may be involved in the maintenance of peripheral T cell tolerance, and is also identified as a potent suppressor of established inflammation. VSIG4 is a phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.